The Maryland-based firm said that the money will support the development and commercialization of a screening test for esophageal squamous cell carcinoma.

CEO Jim Davis said the company is on track to close eight lab acquisition deals this year, though he added that it is now in an "integration and digestion" phase.

The company reported revenues of $2.49 billion, up from $2.30 billion in the year-ago period and above the consensus Wall Street estimate of $2.42 billion.

NEW YORK – After receiving 510 (k) clearance early this month from the US Food and Drug Administration for its sepsis test, Swiss diagnostics company Abionic is targeting the US for further ...